AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
Association of Major Adverse Cardiovascular Events with Varenicline versus Bupropion
By Nguyen R, Xiong F, Sadek R et al.
Background: Cigarette smoking remains a major cause of cardiovascular morbidity and mortality. Varenicline and bupropion are effective smoking cessation therapies; however, their impact on major adverse cardiovascular events (MACE) remains uncertain. Objectives: To evaluate associations between varenicline or bupropion use and major adverse cardiovascular events (MACE), and to compare cardiovascular outcomes between therapies. Methods: We conducted a retrospective cohort study using the TriNetX U.S. Network. Adults aged ≥18 years with a diagnosis of nicotine or tobacco dependence who initiated varenicline or bupropion between January 2000 and January 2024 were compared with those without varenicline or bupropion use respectively. A head-to-head comparison of varenicline and bupropion was performed to evaluate relative cardiovascular risk. Negative-control endpoint analyses were performed. Patients with dialysis dependence or antidepressant use before the index date were excluded. Propensity score matching (1:1) was performed to balance demographics, comorbidities, psychiatric and substance use disorders. Incident outcomes were assessed over 3-year follow-up and included MACE: all-cause mortality, myocardial infarction (MI), stroke, and heart failure. Nicotine smoking cessation, identified as an ICD-10 code, was evaluated as a behavioral outcome. Hazard ratios (HR) with 95% confidence intervals (CI) were estimated using Cox proportional hazards models. Results: After propensity score matching, three cohorts were established: 128,359 patients in the varenicline vs no-varenicline cohort, 152,436 patients in the bupropion vs. no-bupropion group, and 118,234 patients in the varenicline vs bupropion cohort. All cohorts were balanced across covariates including age, sex, BMI, and medical and psychiatric comorbidities (standardized mean differences <0.1). Over 3-year follow-up, varenicline was associated with lower risk of MACE (HR 0.57; 95% CI 0.55-0.59), all-cause mortality (HR 0.50; 95% CI 0.48-0.52), MI (HR 0.72; 95% CI 0.68-0.77), stroke (HR 0.67; 95% CI 0.63-0.72), and heart failure (HR 0.73; 95% CI 0.70-0.77). Bupropion was also associated with lower risk of MACE (HR 0.75; 95% CI 0.73-0.77), mortality, MI, stroke, and heart failure. Both therapies increased smoking cessation (varenicline HR 2.32; 95% CI 2.12-2.53; bupropion HR 2.25; 95% CI 2.06-2.45). In head-to-head analysis, varenicline was associated with lower risk of MACE (HR 0.80; 95% CI 0.77-0.83) and other cardiovascular outcomes, as well as higher continuous abstinence rates (HR 1.09; 95% CI 1.02-1.17). Conclusions: Varenicline or bupropion use was associated with lower risk of MACE, MI, stroke, heart failure, and all-cause mortality over 3 years. Compared with bupropion, varenicline use was associated with greater smoking abstinence and more favorable cardiovascular outcomes.